<DOC>
	<DOCNO>NCT00868140</DOCNO>
	<brief_summary>Our hypothesis hyperinsulinemia increase renal clearance D-chiro-inositol ( DCI ) woman polycystic ovary syndrome ( PCOS ) lead reduction circulate insulin-stimulated D-chiro-inositol-containing inositol phosphoglycan ( DCI-IPG ) release . To assess effect chronic reduction circulate insulin DCI metabolism , propose reduce circulate insulin obese woman PCOS improve insulin sensitivity drug pioglitazone . Pioglitazone thiazolidinedione improve peripheral insulin sensitivity , presumably activation peroxisome proliferator-activated receptor gamma ( PPARÎ³ ) receptor . Administration pioglitazone woman PCOS show improve insulin sensitivity , reduce insulin secretion , decrease fast post-prandial serum insulin concentration .</brief_summary>
	<brief_title>Effects Pioglitazone Insulin Glucose Metabolism Women With Polycystic Ovary Syndrome ( PCOS )</brief_title>
	<detailed_description>This protocol focus hypothesis deficiency putative inositolphosphoglycan ( IPG ) mediator insulin action , namely D-chiro-inositol-containing IPG ( DCI-IPG ) , contribute insulin resistance woman PCOS . Our interest area stem directly previous study , demonstrate administration precursor , D-chiro-inositol ( DCI ) , obese lean woman PCOS improve glucose intolerance reduce circulate insulin , simultaneously improve ovulatory function decrease serum androgen . These finding recently confirm large-scale study independent group . The finding three study suggest administration DCI improve insulin sensitivity PCOS , result improved hormonal metabolic milieu .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Inositol phosphate glycan</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Obese ( Body Mass Index BMI great equal 30 kg/m2 ) woman PCOS 1840 year age : oligomenorrhea ( le 8 menstrual period annually ) biochemical hyperandrogenemia ( elevated total free testosterone ) normal thyroid function test serum prolactin ; AND exclusion 21ahydroxylase deficiency fast 17ahydroxyprogesterone less 200 ng/dl.51 , 2. acceptable health basis interview , medical history , physical examination , laboratory test ( Complete Blood Chemistry CBC , Comprehensive Metabolic Panel denote SMA20 , urinalysis , negative pregnancy test ) . 3 . Signed , witness informed consent . 4 . Ability comply study requirement . 1 . Diabetes mellitus fast glucose oral glucose tolerance test ( OGTT ) , clinically significant pulmonary , cardiac , renal , hepatic , neurologic , psychiatric , infectious , neoplastic malignant disease ( nonmelanoma skin cancer ) . 2 . Current use oral contraceptive . 3 . Documented suspected recent ( within one year ) history drug abuse alcoholism . 4 . Ingestion investigational drug within two month prior study onset .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>